The administration of exogenous recombinant TIMP-2 may sustain normalization of tumor microenvironment by keeping the actions of metzincins under check which may support intact functional ECM and vascularization and may also facilitate a broader window for chemotherapy treatment response [151]. The gene discussed is TIMP2; the disease is neoplasm.